Gossamer Bio (GOSS) Convertible Debt (2020 - 2026)
Gossamer Bio (GOSS) posted quarterly Convertible Debt of $198.8 million for Q1 2026, up 0.51% year-over-year from $197.8 million in Q1 2025, and little changed quarter-over-quarter from $198.5 million in Q4 2025.
Gossamer Bio (GOSS) Convertible Debt (2020 - 2026) Analysis & Trends
Gossamer Bio's Convertible Debt history runs 7 years deep, the most recent figure standing at $198.8 million for Q1 2026.
- In Q1 2026, Convertible Debt rose 0.51% year-over-year to $198.8 million; the TTM figure through Mar 2026 stood at $198.8 million (up 0.51% YoY), while the FY2025 annual figure was $198.5 million, changed 0.5% from the prior year.
- Convertible Debt for Q1 2026 stood at $198.8 million, roughly flat from $198.5 million in the prior quarter.
- The five-year high for Convertible Debt was $198.8 million in Q1 2026, with the low at $195.1 million in Q1 2022.
- The 5-year median for Convertible Debt is $196.8 million (2024), against an average of $196.9 million.
- The sharpest annual moves came in 2022 and 2023: Convertible Debt soared 34.38% in 2022, then rose 0.43% in 2023.
- Gossamer Bio's Convertible Debt stood at $195.7 million in 2022, then advanced by 0.45% to $196.6 million in 2023, then increased by 0.47% to $197.5 million in 2024, then grew by 0.5% to $198.5 million in 2025, then climbed by 0.13% to $198.8 million in 2026.
- Business Quant data shows GOSS's Convertible Debt at $198.8 million in Q1 2026, $198.5 million in Q4 2025, and $198.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.00 Bn | 132.14 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.24 Bn | 60.06 Bn | 1.37 Bn |
| 4 | Moderna | 62.41 Bn | 57.27 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.18 Bn | 27.88 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.93 Bn | 10.54 Bn | 668.28 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - |
| 10 | Gossamer Bio | 47.78 Mn | -9.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 198.76 Mn |
| Dec 31, 2025 | 198.51 Mn |
| Sep 30, 2025 | 198.26 Mn |
| Jun 30, 2025 | 198.01 Mn |
| Mar 31, 2025 | 197.76 Mn |
| Dec 31, 2024 | 197.52 Mn |
| Sep 30, 2024 | 197.29 Mn |
| Jun 30, 2024 | 197.05 Mn |
| Mar 31, 2024 | 196.82 Mn |
| Dec 31, 2023 | 196.59 Mn |
| Sep 30, 2023 | 196.37 Mn |
| Jun 30, 2023 | 196.14 Mn |
| Mar 31, 2023 | 195.93 Mn |
| Dec 31, 2022 | 195.71 Mn |
| Sep 30, 2022 | 195.50 Mn |
| Jun 30, 2022 | 195.29 Mn |
| Mar 31, 2022 | 195.08 Mn |
| Dec 31, 2021 | 150.04 Mn |
| Sep 30, 2021 | 148.38 Mn |
| Jun 30, 2021 | 146.77 Mn |